Favilli S, De Simone L, Mori F, Pollini I, Cecchi F, Zuppiroli A, Manetti A
U.O. Cardiologia, Ospedale A. Meyer, Firenze.
G Ital Cardiol. 1993 Dec;23(12):1195-200.
Dilated cardiomyopathy with impaired left ventricular function is the most common cause of death in patients (pts) with Thalassemia Major (TM) undergoing multiple transfusions. To assess the cardiac status in a young population with TM, 25 pts (mean age 15.8 +/- 5.7 years) and 25 controls (sex and age matched), underwent clinical, echocardiographic and Doppler evaluation. Thirteen pts who received a correct chelation therapy had serum Ferritin (F) below, and nine pts up to 1300 ng/ml. Three out of 9 pts with F > 1300 ng/ml were symptomatic for heart failure, and echocardiography showed a dilated cardiomyopathy. All pts with F < 1300 ng/ml had a normal systolic function. Mean left ventricular (LV) diastolic dimension and LV mass index were significantly increased in pts with TM versus controls (respectively: 37.2 +/- 7.9 mm vs 30.5 +/- 4.3 mm--p < 0.001; 78.6 +/- 16.7 g vs 65.2 +/- 19.4 g--p < 0.05). Moreover, LV end-diastolic dimension was significantly increased in patients with TM having normal systolic function versus controls (36.1 +/- 7.5 mm vs 30.5 +/- 4.3 mm). No difference was found between patients with TM and controls for wall thickness nor for Doppler diastolic indexes obtained from analysis of transmitral flow. Our study suggests that a correct chelation therapy may protect pts with TM from early development of a dilated cardiomyopathy. The first echocardiographic abnormality in pts still asymptomatic and with normal systolic function seems to be an increased end diastolic LV dimension. In our experience, left ventricular filling is not altered in asymptomatic patients.
左心室功能受损的扩张型心肌病是接受多次输血的重型地中海贫血(TM)患者最常见的死亡原因。为评估年轻TM患者的心脏状况,25例患者(平均年龄15.8±5.7岁)和25例对照者(性别和年龄匹配)接受了临床、超声心动图和多普勒评估。13例接受正确螯合治疗的患者血清铁蛋白(F)低于正常水平,9例患者血清铁蛋白高达1300 ng/ml。9例F>1300 ng/ml的患者中有3例出现心力衰竭症状,超声心动图显示为扩张型心肌病。所有F<1300 ng/ml的患者收缩功能均正常。与对照组相比,TM患者的平均左心室(LV)舒张末期内径和LV质量指数显著增加(分别为:37.2±7.9 mm对30.5±4.3 mm - p<0.001;78.6±16.7 g对65.2±19.4 g - p<0.05)。此外,收缩功能正常的TM患者的LV舒张末期内径与对照组相比也显著增加(36.1±7.5 mm对30.5±4.3 mm)。TM患者与对照组在室壁厚度以及经二尖瓣血流分析获得的多普勒舒张指标方面均未发现差异。我们的研究表明,正确的螯合治疗可能使TM患者免于早期发生扩张型心肌病。在仍无症状且收缩功能正常的患者中,超声心动图的首个异常似乎是LV舒张末期内径增加。根据我们的经验,无症状患者的左心室充盈未发生改变。